Integral Derivatives’s AbbVie ABBV Stock Holding History

Integral Derivatives’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-28,024	Closed	-$2.64M	–	1104
2017 Q3	$2.49M	Buy	+28,024	New	+$2.13M	0.05%	259
2017 Q2	–	Sell	-14,242	Closed	-$957K	–	1074
2017 Q1	$928K	Buy	+14,242	New	+$895K	0.02%	549
2016 Q2	–	Sell	-10,354	Closed	-$631K	–	940
2016 Q1	$591K	Buy	10,354 +3,775	+57%	+$210K	0.02%	488
2015 Q4	$390K	Buy	+6,579	New	+$379K	0.01%	715
2014 Q3	–	Sell	-32,847	Closed	-$1.82M	–	1377
2014 Q2	$1.85M	Buy	32,847 +11,683	+55%	+$613K	0.03%	457
2014 Q1	$1.09M	Buy	21,164 +10,088	+91%	+$510K	0.02%	624
2013 Q4	$585K	Buy	+11,076	New	+$544K	0.01%	986

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Integral Derivatives's ABBV Position: Q4 2017 in Review

Integral Derivatives sold out of AbbVie (ABBV) in Q4 2017, closing a stake of 28,024 shares — an estimated $2.64M sold.

Integral Derivatives first reported a position in ABBV in Q4 2013 and held it in 7 quarters. The position peaked at $2.49M in Q3 2017. 2,001 funds tracked by Wall St. Rank hold ABBV as of Q4 2017.

Integral Derivatives reported no remaining AbbVie position as of Q4 2017 after selling out during the quarter.
Integral Derivatives sold 28,024 AbbVie shares in Q4 2017, an estimated $2.64M.
Integral Derivatives first reported a position in AbbVie in Q4 2013 and held it in 7 quarters.
Integral Derivatives's AbbVie position peaked at $2.49M in Q3 2017.
2,001 funds tracked by Wall St. Rank held AbbVie as of Q4 2017.

Based on Integral Derivatives's 13F filing for Q4 2017, filed 14 Feb 2018.